Skip to main content
Top
Published in: AIDS and Behavior 8/2022

Open Access 19-02-2022 | Human Immunodeficiency Virus | Original Paper

PrEP Use, Sexual Behaviour, and PrEP Adherence Among Men who have Sex with Men Living in Wales Prior to and During the COVID-19 Pandemic

Authors: D. Gillespie, Z. Couzens, M. de Bruin, D. A. Hughes, A. Jones, R. Ma, A. Williams, F. Wood, K. Blee, H. S. Bradshaw, R. Drayton, C. Knapper, K. Hood

Published in: AIDS and Behavior | Issue 8/2022

Login to get access

Abstract

We examined PrEP use, condomless anal sex (CAS), and PrEP adherence among men who have sex with men (MSM) attending sexual health clinics in Wales, UK. In addition, we explored the association between the introduction of measures to control transmission of SARS-CoV-2 on these outcomes. We conducted an ecological momentary assessment study of individuals in receipt of PrEP in Wales. Participants used an electronic medication cap to record PrEP use and completed weekly sexual behaviour surveys. We defined adherence to daily PrEP as the percentage of CAS episodes covered by daily PrEP (preceded by ≥ 3 days of PrEP and followed by ≥ 2 days). Sixty participants were recruited between September 2019 and January 2020. PrEP use data prior to the introduction of control measures were available over 5785 person-days (88%) and following their introduction 7537 person-days (80%). Data on CAS episodes were available for 5559 (85%) and 7354 (78%) person-days prior to and following control measures respectively. Prior to the introduction of control measures, PrEP was taken on 3791/5785 (66%) days, there were CAS episodes on 506/5559 (9%) days, and 207/406 (51%) of CAS episodes were covered by an adequate amount of daily PrEP. The introduction of pandemic-related control measures was associated with a reduction in PrEP use (OR 0.44, 95%CI 0.20–0.95), CAS (OR 0.35, 95%CI 0.17–0.69), and PrEP adherence (RR = 0.55, 95%CI 0.34–0.89) and this may have implications for the health and wellbeing of PrEP users and, in addition to disruption across sexual health services, may contribute to wider threats across the HIV prevention cascade.
Appendix
Available only for authorised users
Literature
3.
5.
go back to reference Anderson PL, Glidden D V, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2014;4(151):151ra125. Anderson PL, Glidden D V, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2014;4(151):151ra125.
7.
go back to reference Haberer JE. Current concepts for PrEP adherence in the PrEP revolution. Curr Opin HIV AIDS. 2016;11(1):10–7.CrossRef Haberer JE. Current concepts for PrEP adherence in the PrEP revolution. Curr Opin HIV AIDS. 2016;11(1):10–7.CrossRef
8.
go back to reference Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691–705.CrossRef Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691–705.CrossRef
9.
go back to reference Molina J-M, Charreau I, Spire B, Cotte L, Chas J, Capitant C, et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017;4(9):e402–10.CrossRef Molina J-M, Charreau I, Spire B, Cotte L, Chas J, Capitant C, et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017;4(9):e402–10.CrossRef
10.
go back to reference Haberer JE, Kidoguchi L, Heffron R, Mugo N, Bukusi E, Katabira E, et al. Alignment of adherence and risk for HIV acquisition in a demonstration project of pre-exposure prophylaxis among HIV serodiscordant couples in Kenya and Uganda: a prospective analysis of prevention-effective adherence: A. J Int AIDS Soc. 2017;20(1):1–9. Haberer JE, Kidoguchi L, Heffron R, Mugo N, Bukusi E, Katabira E, et al. Alignment of adherence and risk for HIV acquisition in a demonstration project of pre-exposure prophylaxis among HIV serodiscordant couples in Kenya and Uganda: a prospective analysis of prevention-effective adherence: A. J Int AIDS Soc. 2017;20(1):1–9.
11.
go back to reference Pečavar B, Kokošar Ulčar B, Kordiš M, Pleško M, Turel G, Vovko T, et al. Pre-exposure prophylaxis for HIV with oral tenofovir disoproxil fumarate/emtricitabine in men who have sex with men: Slovenian national demonstration project. Int J STD AIDS. 2021;32(11):1060–5.CrossRef Pečavar B, Kokošar Ulčar B, Kordiš M, Pleško M, Turel G, Vovko T, et al. Pre-exposure prophylaxis for HIV with oral tenofovir disoproxil fumarate/emtricitabine in men who have sex with men: Slovenian national demonstration project. Int J STD AIDS. 2021;32(11):1060–5.CrossRef
12.
go back to reference Goodman-Meza D, Beymer MR, Kofron RM, Amico KR, Psaros C, Bushman LR, et al. Effective use of pre-exposure prophylaxis (PrEP) Among stimulant users with multiple condomless sex partners: a longitudinal study of men who have sex with men in Los Angeles. AIDS Care Psychol Socio-Medical Asp AIDS/HIV. 2019;31(10):1228–33. https://doi.org/10.1080/09540121.2019.1595523.CrossRef Goodman-Meza D, Beymer MR, Kofron RM, Amico KR, Psaros C, Bushman LR, et al. Effective use of pre-exposure prophylaxis (PrEP) Among stimulant users with multiple condomless sex partners: a longitudinal study of men who have sex with men in Los Angeles. AIDS Care Psychol Socio-Medical Asp AIDS/HIV. 2019;31(10):1228–33. https://​doi.​org/​10.​1080/​09540121.​2019.​1595523.CrossRef
13.
go back to reference Jongen VW, Hoornenborg E, van den Elshout MAM, Boyd A, Zimmermann HML, Coyer L, et al. Adherence to event-driven HIV PrEP among men who have sex with men in Amsterdam, the Netherlands: analysis based on online diary data, 3-monthly questionnaires and intracellular TFV-DP. J Int AIDS Soc. 2021;24(5):e25708. Jongen VW, Hoornenborg E, van den Elshout MAM, Boyd A, Zimmermann HML, Coyer L, et al. Adherence to event-driven HIV PrEP among men who have sex with men in Amsterdam, the Netherlands: analysis based on online diary data, 3-monthly questionnaires and intracellular TFV-DP. J Int AIDS Soc. 2021;24(5):e25708.
15.
go back to reference Gillespie D, Knapper C, Hughes D, Couzens Z, Wood F, de Bruin M, et al. Early impact of COVID-19 social distancing measures on reported sexual behaviour of HIV pre-exposure prophylaxis users in Wales. Sex Transm Infect. 2021;97(2):85–7.CrossRef Gillespie D, Knapper C, Hughes D, Couzens Z, Wood F, de Bruin M, et al. Early impact of COVID-19 social distancing measures on reported sexual behaviour of HIV pre-exposure prophylaxis users in Wales. Sex Transm Infect. 2021;97(2):85–7.CrossRef
16.
go back to reference Smiley SL, Milburn NG, Nyhan K, Taggart T. A systematic review of recent methodological approaches for using ecological momentary assessment to examine outcomes in U.S. Based HIV Research. Curr HIV/AIDS Rep. 2020;17(4):333–42.CrossRef Smiley SL, Milburn NG, Nyhan K, Taggart T. A systematic review of recent methodological approaches for using ecological momentary assessment to examine outcomes in U.S. Based HIV Research. Curr HIV/AIDS Rep. 2020;17(4):333–42.CrossRef
18.
go back to reference von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495–9.CrossRef von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495–9.CrossRef
19.
go back to reference De Geest S, Zullig LL, Dunbar-Jacob J, Helmy R, Hughes DA, Wilson IB, et al. ESPACOMP medication adherence reporting guideline (EMERGE). Ann Intern Med. 2018;169(1):30–5.CrossRef De Geest S, Zullig LL, Dunbar-Jacob J, Helmy R, Hughes DA, Wilson IB, et al. ESPACOMP medication adherence reporting guideline (EMERGE). Ann Intern Med. 2018;169(1):30–5.CrossRef
20.
go back to reference Liao Y, Skelton K, Dunton G, Bruening M. A systematic review of methods and procedures used in ecological momentary assessments of diet and physical activity research in youth: an adapted STROBE checklist for reporting EMA Studies (CREMAS). J Med Internet Res. 2016;18(6):1–12.CrossRef Liao Y, Skelton K, Dunton G, Bruening M. A systematic review of methods and procedures used in ecological momentary assessments of diet and physical activity research in youth: an adapted STROBE checklist for reporting EMA Studies (CREMAS). J Med Internet Res. 2016;18(6):1–12.CrossRef
21.
go back to reference Dima AL, Allemann SS, Dunbar-Jacob J, Hughes DA, Vrijens B, Wilson IB. TEOS: A framework for constructing operational definitions of medication adherence based on timelines–events–objectives–sources. Br J Clin Pharmacol. 2020;87(6):2521–33.CrossRef Dima AL, Allemann SS, Dunbar-Jacob J, Hughes DA, Vrijens B, Wilson IB. TEOS: A framework for constructing operational definitions of medication adherence based on timelines–events–objectives–sources. Br J Clin Pharmacol. 2020;87(6):2521–33.CrossRef
22.
go back to reference Urquhart J. The electronic medication event monitor. Clin Pharmacokinet. 1997;32(5):345–56.CrossRef Urquhart J. The electronic medication event monitor. Clin Pharmacokinet. 1997;32(5):345–56.CrossRef
23.
go back to reference Abaasa A, Hendrix C, Gandhi M, Anderson P, Kamali A, Kibengo F, et al. Utility of different adherence measures for PrEP: patterns and incremental value. AIDS Behav. 2018;22(4):1165–73.CrossRef Abaasa A, Hendrix C, Gandhi M, Anderson P, Kamali A, Kibengo F, et al. Utility of different adherence measures for PrEP: patterns and incremental value. AIDS Behav. 2018;22(4):1165–73.CrossRef
24.
go back to reference El Alili M, Vrijens B, Demonceau J, Evers SM, Hiligsmann M. A scoping review of studies comparing the medication event monitoring system (MEMS) with alternative methods for measuring medication adherence. Br J Clin Pharmacol. 2016;82(1):268–79.CrossRef El Alili M, Vrijens B, Demonceau J, Evers SM, Hiligsmann M. A scoping review of studies comparing the medication event monitoring system (MEMS) with alternative methods for measuring medication adherence. Br J Clin Pharmacol. 2016;82(1):268–79.CrossRef
25.
go back to reference Haberer JE, Ngure K, Muwonge T, Mugo N, Katabira E, Heffron R, et al. Context matters: PrEP adherence is associated with sexual behavior among HIV serodiscordant couples in East Africa. J Acquir Immune Defic Syndr. 2017;76(5):488–92.CrossRef Haberer JE, Ngure K, Muwonge T, Mugo N, Katabira E, Heffron R, et al. Context matters: PrEP adherence is associated with sexual behavior among HIV serodiscordant couples in East Africa. J Acquir Immune Defic Syndr. 2017;76(5):488–92.CrossRef
27.
go back to reference Fonsart J, Saragosti S, Taouk M, Peytavin G, Bushman L, Chareau I, et al. Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial. J Antimicrob Chemother. 2017;72(2):478–85.CrossRef Fonsart J, Saragosti S, Taouk M, Peytavin G, Bushman L, Chareau I, et al. Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial. J Antimicrob Chemother. 2017;72(2):478–85.CrossRef
29.
go back to reference Harrell FE Jr. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. New York: Springer; 2001.CrossRef Harrell FE Jr. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. New York: Springer; 2001.CrossRef
30.
go back to reference StataCorp. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC; 2019. StataCorp. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC; 2019.
31.
go back to reference Mboup A, Béhanzin L, Guédou F, Giguère K, Geraldo N, Zannou DM, et al. Comparison of adherence measurement tools used in a pre-exposure prophylaxis demonstration study among female sex workers in Benin. Medicine (Baltimore). 2020;99(21):e20063.CrossRef Mboup A, Béhanzin L, Guédou F, Giguère K, Geraldo N, Zannou DM, et al. Comparison of adherence measurement tools used in a pre-exposure prophylaxis demonstration study among female sex workers in Benin. Medicine (Baltimore). 2020;99(21):e20063.CrossRef
32.
go back to reference Corneli AL, McKenna K, Perry B, Ahmed K, Agot K, Malamatsho F, et al. The science of being a study participant: FEM-PrEP participants’ explanations for overreporting adherence to the study pills and for the whereabouts of unused pills. J Acquir Immune Defic Syndr. 2015;68(5):578–84.CrossRef Corneli AL, McKenna K, Perry B, Ahmed K, Agot K, Malamatsho F, et al. The science of being a study participant: FEM-PrEP participants’ explanations for overreporting adherence to the study pills and for the whereabouts of unused pills. J Acquir Immune Defic Syndr. 2015;68(5):578–84.CrossRef
34.
go back to reference Vaccher SJ, Marzinke MA, Templeton DJ, Haire BG, Ryder N, McNulty A, et al. Predictors of daily adherence to HIV pre-exposure prophylaxis in gay/bisexual men in the PRELUDE demonstration project. AIDS Behav. 2019;23(5):1287–96.CrossRef Vaccher SJ, Marzinke MA, Templeton DJ, Haire BG, Ryder N, McNulty A, et al. Predictors of daily adherence to HIV pre-exposure prophylaxis in gay/bisexual men in the PRELUDE demonstration project. AIDS Behav. 2019;23(5):1287–96.CrossRef
35.
go back to reference Vuylsteke B, Reyniers T, De Baetselier I, Nöstlinger C, Crucitti T, Buyze J, et al. Daily and event-driven pre-exposure prophylaxis for men who have sex with men in Belgium: results of a prospective cohort measuring adherence, sexual behaviour and STI incidence. J Int AIDS Soc. 2019;22(10):1–9.CrossRef Vuylsteke B, Reyniers T, De Baetselier I, Nöstlinger C, Crucitti T, Buyze J, et al. Daily and event-driven pre-exposure prophylaxis for men who have sex with men in Belgium: results of a prospective cohort measuring adherence, sexual behaviour and STI incidence. J Int AIDS Soc. 2019;22(10):1–9.CrossRef
36.
go back to reference Bavinton BR, Vaccher S, Jin F, Prestage GP, Holt M, Zablotska-Manos IB, et al. High levels of prevention-effective adherence to HIV PrEP: an analysis of substudy data from the EPIC-NSW Trial. JAIDS J Acquir Immune Defic Syndr. 2021;87(4):1040–7.CrossRef Bavinton BR, Vaccher S, Jin F, Prestage GP, Holt M, Zablotska-Manos IB, et al. High levels of prevention-effective adherence to HIV PrEP: an analysis of substudy data from the EPIC-NSW Trial. JAIDS J Acquir Immune Defic Syndr. 2021;87(4):1040–7.CrossRef
Metadata
Title
PrEP Use, Sexual Behaviour, and PrEP Adherence Among Men who have Sex with Men Living in Wales Prior to and During the COVID-19 Pandemic
Authors
D. Gillespie
Z. Couzens
M. de Bruin
D. A. Hughes
A. Jones
R. Ma
A. Williams
F. Wood
K. Blee
H. S. Bradshaw
R. Drayton
C. Knapper
K. Hood
Publication date
19-02-2022
Publisher
Springer US
Published in
AIDS and Behavior / Issue 8/2022
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-022-03618-4

Other articles of this Issue 8/2022

AIDS and Behavior 8/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine